Recently, a number of predictors of response to immune checkpoint (ICP) inhibitors (ICPi)—predominantly tissue-based—have been reported, such as the frequency of tumor-infiltrating lymphocytes (TILs), high expression of programmed death ligand 1 (PD-L1) in biopsies as well as microsatellite instability (MSI) and tumor mutational burden (TMB) [2–6]. Here, CD274 is linked to neoplasm.